Magic mushroom therapy tested for cancer caregiver stress

NCT ID NCT07048743

Recruiting now Symptom relief Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether a single high dose of psilocybin, given alongside specialized therapy, can help reduce distress in caregivers of people with advanced cancer. Fifteen caregivers in Ontario will receive the drug and be monitored for safety, feasibility, and changes in anxiety. The goal is to see if this approach is practical and acceptable before larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin
What this could lead to: If successful, this could point toward a new way to reduce anxiety and distress in caregivers of advanced cancer patients.
What could go wrong: This is a very small, early-phase trial with only 15 participants and no placebo group, so results may not apply broadly. Psilocybin can cause temporary psychological distress or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CAREGIVER DISTRESS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CAREGIVER DISTRESS

Contacts and locations

Locations

Toronto General Hospital
RECRUITING

Toronto, Ontario, M5G 2C4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.